Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Abuse, PTSD, & Trauma Topic Center

Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Evi Arthur
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino, Digital Managing Editor
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Tom Valentino, Digital Managing Editor
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network

Perspectives

Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
Lydia Anne Bartholow
Q&As
Utilizing Trauma-Informed Approaches for Collaborative and Empowering Care
06/02/2023
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych...
06/02/2023
Psych Congress Network
Alana Iglewicz, MD
Q&As
Prioritizing Practical Care When Treating Prologued Grief Disorder
09/17/2022
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of...
09/17/2022
Psych Congress Network
Cyrus and Ross
Q&A
Understanding Sociological and Neurobiological Theories Related to Trauma
12/08/2021
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD,...
12/08/2021
Psych Congress Network
Blog
Preparing for COVID-19-Induced PTSD Among Health Care Providers
04/28/2020
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as...
04/28/2020
Psych Congress Network
Q&A
Understanding the Damaging Effects of Trauma
02/20/2020
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD,...
02/20/2020
Psych Congress Network
Blog
Watch for our nation`s post-traumatic reactions
09/18/2017
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye...
09/18/2017
Psych Congress Network
Blog
Vicarious Traumatization in Psychiatrists
10/08/2015
Michael Myers
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical...
10/08/2015
Psych Congress Network
Blog
PTSD in Physicians
09/16/2015
Michael Myers
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of...
09/16/2015
Psych Congress Network
Blog
Where forgiveness fits in the Charleston tragedy
06/22/2015
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important...
06/22/2015
Psych Congress Network
Dr Chepke
Q&As
How should clinicians choose one lithium formulation over another?
09/09/2024
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA,...
09/09/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
Lucia Cheng, MD
Q&As
How to Establish Better Virtual Patient Rapport
09/06/2024
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical...
09/06/2024
Psych Congress Network
Cape Cod Symposium Speakers
Q&As
Exploring the Therapeutic Potential of Psychedelic Treatments in Psychiatry
09/05/2024
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty members Raghu Appasani, MD, PC, Gaetano Vaccaro, PhD, CSAT, and Kaci Hohmann, JD, explore the therapeutic benefits of psychedelics, how psychedelics function as adjunctive therapies, and key legal considerations.
Cape Cod Symposium faculty...
09/05/2024
Psychiatry & Behavioral Health
Dr Tim Wilens
Q&As
Navigating ADHD Treatment Amid the Rise of Social Media and Self-Diagnosis
09/05/2024
Join Tim Wilens, MD, co-director of the Center for Addiction Medicine at Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School, as he discusses innovative, multidisciplinary approaches for managing ADHD beyond...
Join Tim Wilens, MD, co-director of the Center for Addiction Medicine at Massachusetts General Hospital and a professor of psychiatry at Harvard Medical School, as he discusses innovative, multidisciplinary approaches for managing ADHD beyond...
Join Tim Wilens, MD, co-director...
09/05/2024
Psych Congress Network
Olusola Ajilore, MD, PhD
Q&As
A Quick Introduction to Digital Therapeutics for Mental Health Clinicians
08/19/2024
Olusola Ajilore, MD, PhD, provides an overview of digital therapeutics for telehealth practitioners.
Olusola Ajilore, MD, PhD, provides an overview of digital therapeutics for telehealth practitioners.
Olusola Ajilore, MD, PhD,...
08/19/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
Dispelling Common Misconceptions About Sleep Medicine
08/08/2024
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.
Nishi Bhopal, MD, clarifies 5...
08/08/2024
Psych Congress Network
marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network

Videos

andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
Samantha Lau
Videos
The Collaborative Care Approach and Future of Mental Health
02/14/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC,...
02/14/2022
Psych Congress Network
Samantha Lau
Videos
Unpacking Women’s Mental Health Care and Trauma-Informed Psychotherapy
02/01/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC,...
02/01/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
Creating a Crisis Response Plan for Patients With Suicidal Ideation and Trauma-Related Disorders
01/12/2022
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP...
01/12/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
PTSD Comorbid Conditions and Suicidal Ideation Interventions
01/06/2022
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP,...
01/06/2022
Psych Congress Network
Dr. Robin Carhart-Harris on the Power of Psychedelics
Videos
Dr. Robin Carhart-Harris on the Power of Psychedelics
07/22/2020
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head...
07/22/2020
Psych Congress Network
Videos
Robin Carhart-Harris, PhD, Discusses Psychedelics at Davos Forum
02/07/2019
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin...
02/07/2019
Psych Congress Network
Videos
Using Psychedelics in Psychotherapy
10/23/2016
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering...
10/23/2016
Psych Congress Network
Christoph Correll, MD
Videos
Beyond D2 Receptor Manipulation: Novel Agents for Schizophrenia Treatment
10/16/2024
Christoph Correll, MD, provides a thorough pharmacological overview of the traditional and novel treatments available for schizophrenia.
Christoph Correll, MD, provides a thorough pharmacological overview of the traditional and novel treatments available for schizophrenia.
Christoph Correll, MD, provides...
10/16/2024
Psych Congress Network
Christoph Correll, MD
Videos
Recognizing the Early Indicators of Schizophrenia
10/08/2024
Christoph Correll, MD, reviews some of the key prodromal and accentuated psychotic symptoms that serve as early indicators of schizophrenia.
Christoph Correll, MD, reviews some of the key prodromal and accentuated psychotic symptoms that serve as early indicators of schizophrenia.
Christoph Correll, MD, reviews...
10/08/2024
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
Best Practices for Prescribing Long-Acting Injectable Medications Via Telehealth
09/30/2024
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Desiree Matthews, PMHNP-BC, CEO, Different MHP, highlights how providers can integrate medication management into their virtual practices—especially for patients needing long-acting injectable (LAI) antipsychotics.
Desiree Matthews, PMHNP-BC, CEO,...
09/30/2024
Psych Congress Network
Timothy Wilens, MD
Videos
Managing Life Transitions in ADHD: Why Early Preparation is Critical
09/18/2024
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides practical clinical guidance for supporting patients with ADHD through life transitions.
Timothy Wilens, MD, provides...
09/18/2024
Psych Congress Network
Julie Carbray, PhD
Videos
How do novel bipolar disorder agents compare to traditional therapies?
09/04/2024
Join Dr Julie Carbray as she discusses how newer medications are revolutionizing care by addressing the limitations of traditional treatments.
Join Dr Julie Carbray as she discusses how newer medications are revolutionizing care by addressing the limitations of traditional treatments.
Join Dr Julie Carbray as she...
09/04/2024
Psych Congress Network
Julie Carbray, PhD, APRN
Videos
Screening Tools for Adult and Pediatric ADHD
08/22/2024
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, provides a quick overview of some of the most widely accessible screening tools for pediatric and adult attention-deficit/hyperactivity disorder.  
Julie Carbray, PhD, FPMHNP-BC,...
08/22/2024
Psych Congress Network

News

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Evi Arthur
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
Tom Valentino, Digital Managing Editor
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Tom Valentino, Digital Managing Editor
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network
FDA headquarters
News
FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment
10/27/2023
Meagan Thistle
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed...
10/27/2023
Psych Congress Network
News
Second Phase 3 Study of MDMA-Assisted Therapy for PTSD Confirms Findings
09/25/2023
Tom Valentino, Digital Managing Editor
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3...
09/25/2023
Psych Congress Network
A person steps onto a scale
News
Neuropsychiatric Side Effects Reported With CB1 Weight-Loss Drug
10/16/2024
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with...
10/16/2024
Psych Congress Network
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
Increase in Suicidality Associated With FDA Black Box Warning Implementation
10/11/2024
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
News
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
10/09/2024
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may...
10/09/2024
Psych Congress Network
Psilocybin
News
Psilocybin May Improve Outcomes More Than Traditional MDD Treatments
10/08/2024
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with psilocybin and the serotonin reuptake inhibitor (SSRI) escitalopram were associated with long-term improvements in major depressive disorder (MDD) symptom severity, recent phase 2 double-blind, randomized,...
While intensive treatments with...
10/08/2024
Psych Congress Network
dr and patient with brain model
News
Rehospitalization Risk, Treatment Costs Lower With Continued/Maintenance ECT
10/08/2024
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive...
10/08/2024
Psych Congress Network
A midlife woman sits on a couch and looks out the window with her chin resting on her fist.
News
Menopausal Hormone Therapy Benefits Midlife Women With Schizophrenia
10/04/2024
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT)...
10/04/2024
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy.
News
Psilocybin Shows Potential for Depression Treatment, Meta-Analysis Finds
10/03/2024
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin demonstrated an effect similar to escitalopram for the treatment of depressive symptoms in a recent systematic review and meta-analysis published in The BMJ.
High-dose psilocybin...
10/03/2024
Psych Congress Network
FDA approval featuring craig chepke
News
FDA Approves First Schizophrenia Treatment in Over 3 Decades
09/27/2024
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
The US Food and Drug...
09/27/2024
Psych Congress Network
News
Investigational Schizophrenia Drug Hits Primary Endpoint in Phase 2 Trial
09/26/2024
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an investigational oral muscarinic M4 selective agonist in development for adults with schizophrenia achieved its primary endpoint in a phase 2 trial, maker Neurocrine Biosciences announced.
A once-daily, 20 mg dose of an...
09/26/2024
Psych Congress Network

Quizzes

quiz
Quiz
Repeated Ketamine Infusion Shows Improvement for Which Disease State?
06/08/2022
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over...
06/08/2022
Psych Congress Network
Quiz
Quiz: PTSD Found to Be Associated With Symptoms of Which Disorder?
01/13/2020
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found...
01/13/2020
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
LAIs and Telehealth Psychiatric Care
10/24/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
10/24/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Adult ADHD Diagnosis Rates
10/23/2024
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
10/23/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Telehealth Versus In-Person Psychiatric Care
09/19/2024
Do you know what the data from randomized control trials say?
Do you know what the data from randomized control trials say?
Do you know what the data from...
09/19/2024
Psych Congress Network
How many ADHD prescriptions are affected by the med shortage?
Quiz
How many ADHD prescriptions are affected by the med shortage?
09/17/2024
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent...
09/17/2024
Psych Congress Network
Symptom Reduction in Bipolar Disorder Treatment
Expert Insights Quiz
Symptom Reduction in Bipolar Disorder Treatment
09/13/2024
Test your knowledge
Test your knowledge
Test your knowledge
09/13/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
CDC/AAP Treatment Guidelines for Pediatric ADHD
09/11/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
09/11/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement